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1 
Abstract 
Purpose: Our lab has previously shown that patients with early glaucoma have 
dysfunctional vection responses. We attempted to explain this finding using a 
combined index of structure and function (CSFI), originally proposed by Medeiros et 
al. (OVS 2012;130(9):1107-1116) 
Methods: Roll and circular vection were evoked using a back projected screen 
(Experiment 1) and the Oculus RiftTM system (Experiment 2), respectively. The CSFI, 
was obtained using clinical data from visual field tests and optical coherence 
tomography. 
Results: In Experiment 1, the log of vection latency was significantly longer for 
patients with glaucoma (t(21) = 2.39, p < .05). In Experiment 2, vection latency was 
significantly longer for the glaucoma group for both stimulus speeds (F(1,22) = 6.38, 
p = .019). However, the CSFI was not related to vection latency, duration, or rating 
(smallest p = .06). 
Conclusion: In two different studies we replicated the finding that vection 
responses are longer in patients with glaucoma; however, the CSFI is not related to 
vection responses. 
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You will be missed. 
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Introduction 
 
 
Glaucoma 
   Description 
By 2020, a projected 79.6 million people will be diagnosed with glaucoma 
worldwide (Quigley & Broman, 2006). Of that population, 11.1 million will 
completely lose their eyesight, as glaucoma is the second leading cause of 
irreversible blindness worldwide (Quigley & Broman, 2006; Resnikoff et al., 2004; 
Kingman et al., 2004). The prevalence of glaucoma in the United States for 
individuals over the age of 40 was 2.1% between the years 2005-2008, and over 
50% of these individuals did not realize that they had glaucoma (Gupta et al., 2016). 
Self-reported glaucoma prevalence in Canada was found to be around 1.8% between 
2002 and 2003 (Perruccio, Badley, & Trope, 2007). 
Glaucoma is a progressive optic neuropathy that leads to gradual vision loss, 
partially due to optic nerve damage and the death of retinal ganglion cells (RGCs) 
(Quigley, 1999). It can affect one or both eyes, although it is more common to have 
bilateral glaucoma. The resulting vision loss typically begins in the periphery, while 
central visual acuity is spared until later stages of the disease. This pattern tends to 
affect the superior hemifield (corresponding to the inferior retina), forming a 
paracentral arcuate scotoma that can slowly close in on the fovea (Hart & Becker, 
1982). This damage typically occurs in the Bjerrum region, which lies at an 
eccentricity of around 10 to 20 degrees (Morin, 1979). An arcuate pattern of loss 
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forms because the RGC axons travel in an arching pathway around the fovea to 
avoid directly crossing over it. 
Research has shown that central vision can also be affected, even in early 
stage glaucoma (Adams, Heron, & Husted, 1987; Aulhorn & Harms, 1967; Hood et 
al., 2012). Central vision loss may be underestimated due to the nature of the 24-2 
visual field test, which is the most common way to assess the loss of visual function 
in patients with glaucoma. The test points of the 24-2 are spaced 6 degrees apart, 
meaning that the central 4 test points (arranged in a square) will not cover the 
centre-most part of the fovea (Hood et al., 2012). Therefore, the foveal region where 
up to 30% of all RGCs are located is not taken into account, which may lead to 
underreported central vision loss (Curcio & Allen, 1990).  
 
Visual Consequences 
 
Glaucoma is a debilitating disease that can affect many aspects of a patient’s 
life. Visual acuity usually remains intact until the later stages, while peripheral 
vision can be greatly affected. Peripheral vision plays an important role in tasks 
related to motion perception, orientation, and locomotion, which explains why 
patients with glaucoma show difficulties with mobility, balance, hand-eye co-
ordination, driving, and avoiding falls (Friedman et al., 2007; Popescu et al., 2011; 
Kotecha et al., 2009; Kotecha et al., 2012; O’Hare et al., 2012; Black et al., 2011). In 
other words, although these patients can read and perform well on tasks requiring 
sharp visual acuity, they struggle in many other domains. The decreased ability to 
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walk without falling is especially worrisome in this patient population, as they are 
usually senior citizens who are more easily injured. Falls lead to many other 
complications such as broken bones, which further hinder mobility and overall 
quality of life. 
Glaucoma also has many negative effects on visual perception not necessarily 
related to peripheral vision loss. Contrast sensitivity, colour perception, and 
saccadic eye movements are all negatively impacted by glaucoma (Alvarez et al., 
1997; Pearson et al., 2001, Lamirel et al., 2012; Kanjee et al., 2012). Some studies 
suggest that glaucoma not only affects the optic nerve, but that it also alters the 
visual cortex itself. Reduced volume in the visual cortex and lateral geniculate 
nucleus (LGN), as well as in nonvisual regions such and the corpus callosum has 
been shown (Chen et al., 2013; Williams et al., 2013; Gupta et al., 2006, Frezzotti et 
al., 2014). The corpus callosum is integral for relaying information between the two 
hemispheres of the brain, implying that glaucoma could have an effect on much 
more of one’s processing ability than initially thought. 
It has been suggested that glaucoma preferentially damages the 
magnocellular visual pathway, which plays a large role in motion detection (Quigley 
et al., 1987; Anderson & O’Brien, 1997). However, some refute the claim that M cells 
are more affected, stating that all cell types are affected equally (McKendrick et al., 
2007). Although the mechanism behind it is controversial, it is still agreed that these 
patients have difficulties with motion detection (Trick et al., 1994; Silverman, Trick 
& Hart, 1990). 
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 The deficits listed above are all very physically and emotionally taxing on 
patients with glaucoma. It is especially distressing for patients to come to terms 
with the fact that their gradual loss of vision can only be slowed, not stopped. 
Patients with glaucoma have an overall lower quality of life and the disease is often 
co-morbid with major depression, trait anxiety and disturbed sleep (Mills et al., 
2009). Gaining a better understanding of glaucoma is an important first step in 
finding ways to improve the lives of these patients. 
 
Causes and Risk Factors 
 
Intraocular pressure (IOP) is considered to be the main risk factor of 
glaucoma, although it is not a cause. Normal IOP ranges from 12 – 22 mmHg, where 
values above this range are considered to be abnormally high. Open angle and 
closed angle are the most frequent categories of glaucoma. Primary open angle 
glaucoma (POAG) is the most common form, and it generally occurs when the angle 
between the cornea and the iris is too narrow, partially blocking the intraocular 
fluid from draining properly and causing a build up of pressure. The angle may not 
be narrow in some cases, but glaucomatous damage still occurs. In closed angle 
glaucoma, the angle is completely blocked, and pressure can continue to build 
without relief. In these cases, the IOP rises sharply, potentially resulting in 
irreversible vision loss within hours if not treated. Normal tension glaucoma (NTG) 
and low tension glaucoma (LTG) also exists, and these patients still suffer vision loss 
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despite their low IOP. This is why many factors, not just IOP, are important in 
accurately diagnosing glaucoma. 
Glaucoma can also be subdivided into primary and secondary types. Primary 
glaucomas have no identifiable pathological cause, such as NTG and LTG. Secondary 
glaucomas have an identifiable cause, such as a physical injury (traumatic 
glaucoma) or other ocular conditions such as uveitis, pigmentary dispersion 
syndrome and exfoliation syndrome that can lead to uveitic glaucoma, pigmentary 
glaucoma, and pseudoexfoliative glaucoma (PXG), respectively. Uveitis is an 
inflammatory disease of the eye that can result in debris obstructing the trabecular 
meshwork and increasing IOP. The treatment for uveitis is corticosteroids, which 
are also known to elevate IOP and may further contribute to glaucomatous damage. 
Pigment dispersion syndrome is when small pieces of iris pigment flake off and 
block the drainage canals, raising IOP. Similarly, those with exfoliative syndrome 
experience the flaking off of small granules from the outer lens, which also causes a 
blockage. Systemic diseases such as diabetes mellitus can also contribute to 
developing neovascular glaucoma. Diabetes affects the vascular system, putting the 
eye under hypoxic conditions, which can lead to RGC death and optic nerve damage. 
Congenital glaucoma is a more rare form of secondary glaucoma, and it occurs due 
to an innate dysfunction of the trabecular meshwork, which disrupts proper fluid 
drainage. In infantile glaucoma, this defect is present at birth, whereas for juvenile 
glaucoma, it develops around the age of three. 
 Other risk factors for glaucoma include family history, race, age, myopia, 
pigmentary dispersion syndrome, and diabetes (McMonnies, 2016). The actual 
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cause of glaucoma is still widely debated, and many different theories currently 
exist, with the most prevalent being biomechanical and neurodegenerative theories. 
Biomechanical theories of glaucoma aim to explain changes in the eyes—
such as increases in IOP—by applying mechanical laws to biological systems. 
Glaucoma can then be explained in terms of increased IOP causing physical strain on 
the structures within the eye, leading to vision loss. Having a high IOP will primarily 
affect the mechanically weakest point of the eye, which is the optic nerve head 
(Ethier, Barocas, & Downs, 2008; Burgoyne et al., 2005).  
This increase in IOP affects not just the optic nerve head, but many other 
structures. RGC axons are damaged by compression, stretching and shearing forces 
(Ethier, Barocas, & Downs, 2008). The lamina cribrosa has also been shown to be 
negatively impacted, with the resulting shearing forces causing large shape 
deformations (Yan et al., 1994). When these structures change their shape, it can 
lead to a reduction of blood flow to nearby axons, further damaging RGCs (Quigley 
et al., 1984; Ethier, Barocas, & Downs, 2008). 
The main problem for biomechanical explanations of glaucoma are the many 
cases of patients with low IOP who exhibit optic nerve damage. It has been proposed 
that individual biomechanical differences in optic nerve head structure and 
sensitivity to pressure exist, meaning that some individuals have lower thresholds 
for the level of IOP necessary to cause harm (Ethier, Barocas, & Downs, 2008; Yan et 
al, 1994). In fact, it may not just be differences in optic nerve head physiology, but a 
combined result of different connective tissue geometry, rigidity, and the amount of 
blood flow (Downs, Roberts, & Burgoyne, 2008). 
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Berdahl et al. (2008) support the theory that IOP leads to glaucoma, with the 
caveat that high IOP is only harmful if the cerebrospinal fluid pressure on the other 
side of the eye is low. If pressure is equalized, the optic disc is not under any strain 
and the risk of glaucomatous vision loss is minimized. Cases of patients with high 
IOP would then be protected from vision loss if they also had high cerebrospinal 
fluid pressure. This theory also explains how patients with LTG may still experience 
vision loss, as IOP is not the only determinant factor.  
Neurodegenerative theories seek to explain glaucoma as a neurological 
disease that affects not just the eyes, but cortical structures as well. A post-mortem 
case study by Gupta et al. (2006) showed a patient with neurodegeneration in the 
optic nerve, posterior LGN, and part of the visual cortex just below the calcarine 
sulcus. This neural loss correlated with a superior visual field defect that was seen 
before the patient’s death. This was the first study to demonstrate that 
neurodegeneration beyond the optic nerve occurs in patients with glaucoma. Gupta 
et al. (2009) later went on to conduct an in vivo study using MRI to further 
demonstrate LGN degeneration in patients with glaucoma. LGN and visual cortex 
degeneration has been confirmed by other research groups (Zhang et al., 2012; 
Zikou et al., 2012; Wang et al., 2016). Activation of the visual cortex also appears to 
be reduced as glaucoma’s severity increases, demonstrating that the 
neurodegeneration seen in glaucoma is progressive (Murphy et al., 2016).  
It is generally thought that RGC death and optic nerve damage occur first, 
while visual cortex neurodegeneration comes afterwards (Calkins & Horner, 2012); 
therefore, the deterioration of brain structures past the optic nerve is likely not a 
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cause of glaucoma, but rather a result of the disease’s natural progression via 
anterograde trans-synaptic degeneration (Calkins & Horner, 2012). For example, 
patients with early stage POAG do not show any changes in grey matter volume (Li 
et al., 2012).  
There has been an attempt to find commonalities between glaucoma and 
Alzheimer’s disease in order to propose a neurodegenerative theory for the cause of 
glaucoma. Glaucoma resembles Alzheimer's in many ways, such as the fact that both 
are chronic, progressive, age-dependent neurodegenerative diseases. McKinnon 
(2003) refers to glaucoma as an “ocular Alzheimer’s disease”, suggesting that RGC 
death occurs due to a similar apoptotic cascade as in Alzheimer’s disease. In 
Alzheimer’s disease, the capase-3 protease cleaves an amyloid precursor protein, 
creating amyloid beta plaques. These plaques are neurotoxic, causing the apoptosis 
of neurons. A rat glaucoma model showed that RGC death occurred through the 
same apoptotic cascade as seen in Alzheimer’s disease (McKinnon, 2003; McKinnon 
et al., 2002). Apoptotic RGCs have also been shown to be significantly more present 
in patients with glaucoma than in age-matched controls (Kerrigan et al., 1997). 
Apoptosis may cause increases in IOP as death of trabecular network cells can cause 
the beams to collapse and disrupt the flow of intraocular fluid (McKinnon, 2003; 
Agarwal et al., 1999). 
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Detection 
 
 RGC loss often happens well before any changes in vision are noted by the 
patient. Around 35-50% of RGCs can die before visual field tests will begin to show 
any deficits (Kerrigan-Baumrind et al., 2000; Falkenberg & Bex, 2007; Quigley, 
Dunkelberger, & Green, 1989). At this point, it is too late to restore vision that has 
already been lost.  
 In order to detect glaucoma at an early stage, patients with certain risk 
factors (such as ocular hypertension, narrow angles, or a family history of 
glaucoma) are monitored by their clinician. These high risk groups should be seen 
by their clinician at regular intervals to check for any suspicious developments. In 
conjunction with screening for risk factors, clinicians also use a battery of tests to 
diagnose glaucoma and track its progression. There is not a single, determinant 
factor that is indicative of glaucoma, which is why many attributes need to be taken 
into account in order to make an accurate diagnosis. These clinical tests can 
generally be split into measures of structure and function. 
Structural diagnostic tests can assess IOP, the level of angle closure, optic 
disc and optic nerve damage, and the retinal nerve fiber layer thickness (RNFL). 
 Tonometry is used to assess IOP, which is the main risk factor for glaucoma. A small 
device is placed on the cornea to measure pressure in mm Hg. If the pressure 
appears high, the angle between the iris and cornea can be measured using 
gonioscopy to ensure that it is not blocked or too narrow. If the angle is too narrow 
or completely closed, surgery may be proposed to reduce the IOP. 
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Optic disc “cupping” is also investigated to look for optic nerve damage using 
ophthalmoscopy. Pathological cupping occurs when the central area of the optic disc 
(which is a small pit where the optic nerve exits that has no photoreceptors) 
increases in size, encroaching on the healthy area of retina that makes up the outer 
segment of the optic disc. The amount of cupping can also be measured in a ratio of 
the cup to the disc using a retinal imaging device called optical coherence 
tomography (OCT). OCT also looks at retinal nerve fiber layer thickness (RNFL), as a 
thinner layer can indicate RGC death.  
Functional tests look at the visual functioning of the patient. Visual field tests 
are the gold standard for testing peripheral visual function. The visual field test 
measures the patient’s responses to flashing lights to find areas of poor visual 
functioning. Testing central visual acuity regularly is also important, but problems 
usually do not arise until moderate to late stage glaucoma.  
OCT and visual field tests, which are the main tests used to monitor glaucoma 
progression, are further detailed in Appendix A. 
 
Treatment 
 
Current pharmaceutical treatments for glaucoma can slow down vision loss, 
but cannot stop the progression of the disease. Glaucoma-treating eye drops work 
by either reducing the amount of intraocular fluid production (e.g., beta-blockers) or 
increasing the rate of drainage within the eye (e.g., prostaglandin-related drugs). 
IOP is the main target for treating glaucoma, and IOP-lowering drops are effective 
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even in patients with LTG and NTG. Although IOP is already normal in these 
patients, further reducing IOP by 30% has been shown to significantly decrease 
visual field progression (Collaborative Normal-Tension Glaucoma Study Group, 
1998). 
In cases where IOP cannot be controlled with eye drops alone (such as when 
the angles are very narrow or closed), surgery is used to create alternative drainage 
pathways for the intraocular fluid to flow more freely.  
The most common IOP-lowering surgery for glaucoma is trabeculectomy. 
This surgery removes part of the trabecular meshwork and Schlemm’s canal, re-
directing intraocular fluid through a series of flaps in the sclera to a reservoir or 
bleb (Weinreb & Crowston, 2005). The flaps are sutured in a way that ensures the 
intraocular fluid does not flow into the bleb too rapidly and cause it to burst or leak. 
Removing part of the trabecular meshwork allows for fluid to flow more easily, and 
the newly created bleb provides an extra space when there is a buildup of fluid in 
the eye. The bleb is located just under the surface of the sclera, usually hidden 
behind the upper eyelid. Part of the iris may also be removed during this surgery in 
an iridectomy, as the iris can potentially block the drainage pathway to the bleb. 
(Weinreb & Crowston, 2005). Similarly, an iridotomy uses a laser to create a small 
hole in the iris. Iridectomy or iridotomy can be performed without trabeculectomy, 
as creating an extra drainage pathway through the iris can also help reduce IOP. 
A shunt or stent is a small, silicone tube that creates an open channel for 
intraocular fluid to drain into a reservoir called a plate (similar to a bleb) just 
underneath the sclera (Weinreb & Crowston, 2005). The fluid from the plate is then 
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gradually absorbed by the conjunctival blood vessels of the eye. This method is not 
as effective at reducing IOP, and therefore it is not the best choice for those with 
advanced glaucoma. Shunts or stents may be used as an alternative solution if 
trabeculectomy fails (Weinreb & Crowston, 2005). 
 
Structure-Function Relationship 
 
There are varying differences in the onset of the deterioration of function 
(visual acuity and overall visual functioning) and structure (RGC death and optic 
nerve damage) across patients with glaucoma. In the early stages of the disease, 
patients may have extensive RGC loss but still maintain 20/20 vision or better when 
reading (Klein et al., 1995). Due to the relatively high remaining visual function 
despite the RGC loss, it is not possible to detect glaucomatous abnormalities with 
visual field tests alone. However, there are some cases where functional changes 
occur first, or at the same time as structural changes. 
As glaucoma advances, visual function appears to deteriorate at a faster rate 
than structure (Malik & Garway-Heath, 2012). Therefore, the relationship between 
visual field tests and structural measures (such as neuroretinal rim area) is thought 
to be curvilinear in nature (Garway-Heath et al., 2002). In other words, RGC loss 
occurs abundantly in very early stages of the disease, despite the fact that visual 
field loss is not apparent. In later stages of the disease, RGC loss tapers off and visual 
field loss occurs at a much more noticeable rate. Many have sought out to find the 
ideal model to describe how the loss of structure versus function occurs over time. 
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This is essential for estimating the rate at which glaucoma can progress in patients, 
allowing for potentially better patient management and treatment.  
Harwerth et al. (2010) created a model for linking structural loss to 
functional loss by looking at a glaucoma disease model in monkeys. He trained the 
monkeys to perform visual field tests, and enucleated them 2 days after this test to 
obtain a histological RGC count (Harwerth et al., 2004). His model showed that RGC 
loss and visual field test sensitivities were linearly related at each eccentricity, when 
both measures were expressed in logarithmic units (Harwerth et al., 2004). Visual 
field tests are normally obtained on a logarithmic scale while OCT results use a 
linear scale. Transforming the data improves the accuracy of the model (Harwerth 
et al., 2004). These animal studies were crucial for developing an initial framework 
that could be tested out empirically with histological RGC counts, as opposed to 
estimates based on OCT results. 
Harwerth extended his model to a human population, formulating the 
Harwerth Non-Linear Model (H-NLM). Instead of a post-mortem histological count, 
RGCs were estimated based on the thickness of the RNFL around the optic disc from 
time domain OCT (Harwerth et al., 2004; Harwerth et al., 2010). Since this method 
does not directly measure the number of RGCs, a topographic map had to be used in 
order to estimate where the RGC axons and their corresponding bodies lie. 
The most recent version of the model includes a correction factor for age and 
glaucoma severity (Harwerth et al., 2008; Harwerth et al., 2010). 
Raza and Hood (2015) later critiqued Harwerth’s model, finding RGC 
estimates that were much greater than what would be expected based on human 
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histological studies (Curcio & Allen, 1990). The H-NLM estimates RGC counts using 
only the region of the retina assessed by the 24-2 visual field test, which does not 
take into account the extreme periphery of the retina. This difference in area may 
explain why overall RGC estimates are consistently larger when determined with 
OCT as compared to visual field tests. In addition, the correction factors for age and 
disease severity may not necessarily increase the accuracy of the model. The H-NLM 
overestimates the amount of RGC axon loss that typically occurs with age at a rate 
that’s 2 to 4 times greater than human histological reports (Raza & Hood, 2015). 
Hood and Kardon (2007) proposed the Hood and Kardon linear model (HK-
LM), which is based on an earlier study by Hood et al. (2002) comparing visual 
sensitivity to multifocal visual evoked potentials. Multifocal visual evoked potentials 
are objective visual field tests that measure a patient’s response to points of light 
using electrodes placed on the scalp. The RGC layer of the macula is measured 
directly as opposed to inferring RGC axons from the optic disc. The HK-LM posits 
that OCT results should have a linear relationship with visual field test sensitivities 
when both measures are expressed in linear units. The smaller number of 
assumptions about RGC axons is thought to lead to a model with a higher accuracy. 
This is possible through a newer form of OCT, frequency-domain OCT.  
Unlike the H-NLM model, age or disease severity were not included in the 
HK-LM model. When directly comparing the two models, the HK-LM was more 
accurate than the H-NLM when both were run on the same data set of patients and 
suspects (Raza & Hood, 2015). 
 
 
15 
The original model Harwerth et al. (2010) developed to describe 
glaucomatous monkeys was adapted by Medeiros et al. (2012) to create the 
Combined Index of Structure and Function (CSFI). The CSFI is a weighted calculation 
using structural and functional data to estimate the amount of RGC loss, compared 
to the expected number in a healthy individual of the same age. The principle behind 
the CSFI is that combining structural and functional data should provide a more 
accurate assessment of glaucomatous disease staging than using the tests 
separately. The formula behind the CSFI also takes other aspects into account, such 
as age and visual field eccentricities, as well as changing numerous factors to be 
applicable to humans as opposed to monkeys. More can be read about the specific 
calculations used for the CSFI in the Methods section. 
However, the results of the CSFI differ from Harwerth’s H-NLM, despite the 
fact that this is where it is derived from. On average, RGC estimates based on OCT 
results are lower than those obtained from visual field tests (Raza & Hood, 2015). 
The opposite was seen for Harwerth’s H-NLM. This discrepancy may be because the 
mean axon diameter for humans is 0.5-0.7μm in histological studies, but Harwerth 
uses 0.9μm for his model (Fitz-Gibbon & Taylor, 2012; Swanson & Horner, 2015), 
which would lead to underestimating the number of RGCs in early stage glaucoma. 
Despite the discrepancies in estimating exact RGC numbers, the CSFI has 
proven itself to be a fairly reliable measure for glaucomatous staging. It can assess 
the degree of damage in patients with very early stage glaucoma (Tatham, Weinreb, 
& Medeiros, 2014) and is also more accurate at detecting glaucoma than using 
structural or functional measures in isolation (Medeiros et al., 2012a).  
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Our lab has been unable to find clinical measures that explained weaker 
vection responses in patients with glaucoma (Tarita-Nistor et al., 2014). The CSFI 
may be a clinical measure that is related to vection responses in these patients. 
 
Vection 
Description  
 
Vection is the illusory sensation of self-motion that occurs when a stationary 
observer views a large, moving scene. The most common real life example of this 
occurs when someone in a stationary train looks out the window to see the train on 
the adjacent track begin to move but feels like she/he is actually moving. The feeling 
that the stationary train is actually the one that is moving is called vection. It is 
unusual for an entire scene to be moving in nature, so it is more practical for our 
brains to assume that we are the ones in motion (Howard, 1986). Vection can be 
subdivided into roll vection (rotation on the roll axis), circular vection (rotation 
around the yaw axis), and linear vection (forward or backward motion). 
The pattern of movement of a large scene across the retina resulting from the 
relative motion between an observer and their environment is called optic flow 
(Gibson, 1950). For example, walking forward while looking straight ahead 
produces optic flow, with the environment appearing to expand from a central 
point. Optic flow is an important visual cue for determining our heading and 
maintaining postural stability during locomotion.  
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 Optic flow may also occur when an observer is stationary but is viewing the 
motion of a scene as it passes by. This is rare in nature but occurs, for example, 
when we sit on a stationary vehicle (say, a train) while another large vehicle moves 
beside it. This phenomenon is reproduced in controlled laboratory experiments 
where seated observers are shown large, moving scenes on a monitor or a headset. 
In this case, the optic flow field mimics what would be seen by the observer moving 
through a scene but, during vection, there is no physical self-motion and the 
vestibular, somatosensory and proprioceptive information can be cancelled by the 
visual input. When optic flow is the only cue to self-motion, observers experience 
vection because visual information takes precedence over the vestibular and other 
inputs that register no real self-motion. 
Vection involves a combination of inputs from the visual system, the 
vestibular system, the somatosensory system and the proprioceptive system 
(Dichgans et al., 1978). The illusion of vection occurs due to the visual input 
overriding the vestibular input, causing the brain to interpret the large moving 
scene as being a result of self-motion instead of the motion of an external image 
(Palmisano et al., 2011). It is possible to adapt to this sensation after staring at a 
vection stimulus for an extended period, as the vestibular system will eventually 
resolve the illusion (Palmisano et al., 2011).  
Current fMRI studies show mixed results for precisely which areas of the 
brain are activated during vection. Vection responses to an optic flow stimuli caused 
greater activity in the middle temporal cortex, V6, the ventral intra-parietal area, 
and the parieto-insular vestibular cortex, compared to conditions where vection 
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responses were not present (Uesaki & Ashida, 2015). These data show some overlap 
with the results of Wall & Smith (2008) and Kovacs, Raabe, & Greenlee (2008). Wall 
& Smith (2008) found preferential activation for optic flow that was consistent with 
cues for egomotion (as opposed to inconsistent with egomotion) in the ventral 
intra-parietal area and the cingulate sulcus visual area (Wall & Smith, 2008). Vection 
induced from a three-dimensional optic flow field activated the middle temporal 
cortex, precuneus, and the dorsal region of the intraparietal sulcus (Kovacs, Raabe, 
& Greenlee, 2008). The optic flow field displayed a three-dimensional area of dots 
that appeared to pop out of the screen towards the viewer. 
Brandt et al. (1998) showed that during the experience of vection, areas of 
the vestibular system were suppressed. This would be consistent with the theory 
that vision dominates, allowing one to feel motion even when the body is remaining 
entirely still. However, Nishiike et al. (2002) showed both visual and vestibular 
systems activating in unison—without any vestibular suppression. These various 
differences in results in terms of which areas are activated may be simply due to 
differences in methodology and differences in vection stimuli. A consensus has yet 
to be reached on how the brain triggers the sensation of self-motion, as it involves a 
complex interplay between various sensory systems. 
 
Response Strength  
 
Peripheral vision plays a large role in motion detection, which is very 
important in inducing vection responses. Several studies have shown that vection 
 
 
19 
responses are stronger when a moving display is shown to the peripheral visual 
field (Held et al., 1975; Johansson, 1977; Keshavarz & Berti, 2014). For example, 
Brandt, Dichgans, & Koenig (1973) showed that circular vection could be 
consistently induced by peripheral displays 30 degrees in size, but not by central 
displays of the same size. Up to 120 degrees of central vision could be obstructed, 
and participants still reported vection responses. Another study by Tarita-Nistor 
(2008) also demonstrates this notion. In age-related macular degeneration, patients 
develop central scotomas, which can be thought of as a natural way to occlude 
central vision. Much like the healthy participants who still felt vection strongly when 
shown only peripheral displays in the study by Brandt, Dichgans, and Koenig 
(1973), Tarita-Nistor et al. (2008) found that patients with age-related macular 
degeneration experience a stronger sensation of vection compared to controls.  
However, other researchers refute the claim that stimulus eccentricity alone 
modulates vection responses. In attempting to replicate the study by Brandt, 
Dichgans, and Koenig (1973), Post et al. (1988) showed that vection could be 
induced by showing a 30 degree display to the centre. This refuted the theory of 
peripheral dominance for inducing vection responses. Howard and Heckmann 
(1989) put forth an argument to explain the discrepancy between these two 
findings, proposing that depth modulated vection responses. They tested this by 
showing a 54 by 44 degree central motion display either in front or behind of a 
rotating drum. The near central display produced less than half of the vection 
response of the far display. Vection responses could also be generated for central 
vision displays that were only 13.5 degrees. Therefore, motion stimuli that are 
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farther away and perceived as being in the background produce stronger vection 
responses. The Brandt et al. (1973) study likely created a foreground-background 
illusion, making it more difficult to experience vection with the central-only display, 
as it appeared in the foreground.  
It is now accepted that peripheral vision is not the sole factor that results in 
stronger vection responses. Stimulus eccentricity can interact with other factors 
such as depth cues to alter the experience of vection. For example, the functional 
sensitivity hypothesis was proposed by Warren and Kurtz (1992) to explain that 
central and peripheral vision have different sensitivities to specific types of visual 
information, which is what leads to a discrepancy in vection response strength. 
Peripheral vision is thought to be specialized for detecting lamellar flow, in 
comparison to central vision which is specialized for both lamellar and radial flow 
(Warren & Kurtz, 1992).  Radial flow has a pattern of movement where there is an 
expansion of points from one central spot. Lamellar flow is composed of vertical 
motion. Spatial frequency is another factor that affects vection responses, as an 
interaction was found between the spatial frequency of optic flow and eccentricity 
(Palmisano & Gillam, 1998). A peripheral stimulus produced the strongest sensation 
of vection when the stimulus had a high spatial frequency, whereas vection was 
weakest for a low spatial frequency.  
Vection can also be strengthened by altering other factors of the stimulus, 
such as increasing the speed, or having a more densely populated pattern, up to a 
certain threshold (Brandt et al., 1973; Seno, Ito, & Sunaga, 2009). 
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Vection response strength can vary by observer. For example, circular 
vection responses are stronger in older populations (Paige, 1994). Males tend to 
experience significantly longer latencies for circular vection than females 
(Darlington & Smith, 1998). In addition, attention also appears to have an effect on 
vection, as when shown two opposing stimuli at once, vection is perceived in the 
direction corresponding to only the attended stimuli (but only when there are no 
depth cues) (Kitazaki & Sato, 2003). In a previous study, Tarita-Nistor et al. (2014) 
showed that patients with early stage glaucoma have a significantly weaker 
sensation of vection compared to controls with healthy vision.  
The purpose of this thesis is to explain the presence of weaker vection 
responses in patients with early stage glaucoma using the CSFI in two experiments. 
 
 
General Method 
Overview 
Our lab has demonstrated that patients with glaucoma exhibit a weaker 
sensation of vection (Tarita-Nistor et al., 2014). However, Tarita-Nistor et al. (2014) 
could find no clinical tests that explained why these weaker responses occurred. 
The following two experiments tested vection responses in patients with 
early stage glaucoma and controls with normal vision. This study seeks to explain 
these weaker vection responses in terms of CSFI; an estimate of RGC loss that uses 
values from both OCT and visual field tests. By drawing information from tests 
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looking at both structure and function, the CSFI is a useful model for staging 
glaucoma that draws from both domains instead of just one. 
The two experiments have different set-ups for inducing vection, with one 
being shown on a back-projected screen and the other on the Oculus Rift headset. 
The projection screen was initially used because it was large enough to cover most 
of someone’s visual field. However, a large number of patients did not experience 
vection at all using this projection screen, so we used the more immersive Oculus 
Rift system in Experiment 2 to try to decrease this number. 
 
Inclusion and Exclusion Criteria 
The patients were medically treated to normalize their IOP. Mild glaucoma 
was defined as having central visual acuity at 20/40 or better, visual field mean 
deviations (MD) no lower than -5 dB, and no pronounced optic disc damage.  All 
patients were undergoing treatment, and had a confirmed diagnosis of bilateral, 
open-angle glaucoma from their ophthalmologist at the Eye Clinic in Toronto 
Western Hospital. Controls were excluded if they were suspected of having an 
undiagnosed case of glaucoma due to family history, high IOP, or other ocular 
abnormalities. All cases of closed-angle glaucoma, other complicating ocular 
diseases (such as amblyopia or diabetic retinopathy), diabetes, vestibular system 
dysfunctions (such as vertigo), neurological diseases, or cognitive impairments were 
excluded. Any participant with a spherical refraction error worse than ±5 D was also 
not included.  
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Recruitment 
Patients were recruited via thorough chart reviews at Toronto Western 
Hospital’s Eye Clinic. Patients meeting the study criteria were contacted over the 
phone and asked if they were willing to participate in a study an hour before their 
regular appointment at the Eye Clinic. Controls were recruited using flyers posted 
around Toronto Western Hospital. The flyers provided our phone number so we 
could screen participants for eligibility via a phone interview before booking an 
appointment. 
All participants provided informed consent (see Appendix C) after the study 
was described to them in detail. This research project was approved by the 
University Health Network Research Ethics Board and the Ethics Board of York 
University, and is in accord with all of the tenets of the declaration of Helsinki. 
 
Clinical Tests 
All participants underwent monocular visual field testing using the 
Humphrey Field Analyzer (model HFA-II 750; Carl Zeiss Meditec, Dublin, CA). The 
24-2 Swedish Interactive Threshold Algorithm (SITA) standard was used to assess 
light sensitivity in decibels at each eccentricity as well as the mean deviations (MD). 
Visual field tests with fixation losses over 33% or false positive responses over 20% 
were considered unreliable and therefore discarded.  
Using Spectral Domain OCT (model Cirrus; Carl Zeiss Meditec, Dublin, CA), a 
200 x 200 optic disc cube protocol scan was taken. This was used to obtain the cup-
to-disc ratio, the optic disc area, and the retinal nerve fiber layer (RNFL) thickness. 
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For patients, we used OCT and visual field results from their most recent visit to the 
ophthalmologist. If clinical data was older than 6 months from the scheduled date of 
psychophysical testing, we did not recruit that patient. For controls, these tests were 
performed before the vection evaluation. 
 
Psychophysical Tests 
Best-corrected visual acuity was measured monocularly (OD and OS) using a 
computerized version of the Early Treatment Diabetic Retinopathy Study (ETDRS) 
test. In Experiment 2, we used the computerized version of the ETDRS to also test 
binocular visual acuity. The distance between the viewer and the display was 6 m.  
Both experiments tested vection using a different apparatus and stimulus, 
which are explained in detail in the Methods section for each experiment. 
Participants sat in a dark room and viewed a full-field, moving stimulus of white 
dots on a black background. Participants reported their vection latency and 
duration by pressing and holding the button of a button-response box. An additional 
measure of vection was used in each study, such as perceived or actual body tilt 
(Experiment 1), or a subjective vection strength rating (Experiment 2). 
 
Data Analysis 
One of our measures for correlating vection responses to clinical measures in 
patients with glaucoma was the CSFI, which combines the weighted average of 
structural (OCT) and functional (visual field) data into an equation to calculate the 
percentage of RGC loss for each eye (Medeiros et al., 2012; Tatham et al., 2014). 
 
 
25 
Calculating RGC loss is a multiple step equation that uses various clinical and 
demographic values.  
First, using values from visual field tests (also called Standard Automated 
Perimetry or SAP), the SAPrgc is calculated. This is a weighted average that uses 
sensitivity measurements from the visual field test at each eccentricity, to estimate 
the number of RGCs (see Appendix A for how the visual field values were obtained). 
An RGC estimate is formulated for each location on the retina, and these are added 
up to make the total estimate.  
 
 
 
 
                                                      (1) 
                                                        (2) 
      
          
 
                                                       (3) 
             
        
                                                   (4) 
 
 
m = slope 
b = intercept 
gc = ganglion cell quantity (dB) 
 s = sensitivity (dB) 
ec = eccentricity 
 
 
 
The values m and b are part of a linear function that plots ganglion cell 
quantity and the sensitivity value for that eccentricity. Therefore, the SAPrgc is the 
sum of the RGC estimate for each eccentricity, corresponding to a different area of 
the retina. This sum, in equation 4, is composed of all 54 points in the visual field 
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test. Note that ganglion cell quantity and visual field sensitivity are both expressed 
in db, which is a logarithmic scale, to stay consistent with the logarithmic scale used 
for visual field results. 
Secondly, the OCTrgc is calculated. The OCTrgc is another RGC estimate, but 
this equation uses primarily structural data obtained from OCT scans. Some 
functional data from visual field tests are also used. 
 
                                                           (5) 
                                                          (6) 
                                                                                   (7)          
 
 
d = axonal density 
c = correction factor  
MD = mean deviation (from visual fields) 
 
 
The axonal density (axons per micrometer squared) estimation takes age 
into account, since the density of the optic nerve degrades over time. The correction 
factor is to adjust for the severity of the disease.  
Thirdly, the SAPrgc and the OCTrgc values are combined to calculate the 
weighted RGC count (wrgc). Changes in RNFL thickness (OCT values) are generally 
much easier to detect than visual field values in early stage glaucoma. Therefore, 
OCTrgc is weighted higher in patients with early stage glaucoma, while SAPrgc is in 
advanced glaucoma. The wrgc is a more accurate estimate of the number of RGCs 
than OCTrgc or SAPrgc alone (Medeiros et al., 2012). 
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                               (8) 
 
 
The lowest visual field value possible is -30dB, which is why the MD is 
divided by 30.  
Finally, the wrgc has to be transformed to the CSFI, which is the percentage 
of total RGC loss based on the expected amount of RGCs a healthy person of that age 
should typically have. In order to do this, Medeiros et al. (2012) had to use estimates 
for what the expected number of RGCs would be for a healthy individual. A linear 
regression model was created relating wrgc to age and optic disc area in a control 
population. The model was then used as a predictor of RGC number based on one’s 
age and optic disc area. The CSFI finds the difference between the wrgc and the 
expected RGC count (from the linear regression model), and then converts it to a 
percentage out of 100. Therefore, A CSFI of 25 indicates that 25% of RGCs have died 
(based on the expected amount of RGCs that should be present). A negative CSFI 
value indicates a surplus of RGCs compared to the expected amount.  
 
 
                                         
                                              (9) 
 
      
                       
                 
                                         (10) 
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Experiment 1 
In this experiment, vection was induced using a large, moving dot pattern 
displayed on a projection screen. When vection was experienced, this stimulus 
caused participants to tilt their body in the opposite direction of rotation, allowing 
us to measure body tilt as an indicator of vection strength. Vection latency and 
duration was measured as well. In addition, clinical measures were taken in order to 
calculate the CSFI and determine disease severity. 
 
Participants 
We tested 22 (mean age, 70.3 [±6] years) patients with mild glaucoma. 27% 
(6/22) were female.  The mean IOP of both eyes for this group was within the 
normal range (13.0 [±4] mm Hg). The patient population consisted of two people of 
Asian descent, and one of African descent, while the rest of the group was white.  
In addition, 18 controls with healthy vision were tested. Of those, we used 11 
(mean age, 55.5 [±9] years) for the analysis (see Table 2 caption for reasons for 
exclusion). Thirty-six percent (4/11) were female. Although our initial intention was 
to collect age-matched data in the control group, we had problems recruiting 
suitable participants, so exceptions had to be made in order to obtain a large enough 
sample. As a result of this, the controls were significantly younger than the 
glaucoma group , t(21) = 4.40, p < 0.001. Of all the participants, only one control was 
of African descent, which is a population that is 5-6 times more likely to develop 
POAG than Caucasians (Tielsch et al., 1991). 
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Demographic Information 
TABLE 1. 
Demographic Information of Patients with Glaucoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IOP values were from the date of testing, but this was looked up after the entire study 
was finished. Unfortunately, some patients no longer had charts available at the clinic 
at that time, preventing IOP values from being obtained. 
 
 Visual Acuity (logMAR) IOP 
ID Diagnosis Age (years) Gender OD OS OD OS 
G1 POAG 67 M -0.02 0 15 15 
G2 POAG 73 M -0.04 -0.04 12.5 10 
G3 POAG 68 F -0.1 -0.1 12.5 12 
G4 LTG 65 M -0.1 -0.1 17 13 
G5 POAG 74 M 0.2 0 15 16 
G6 LTG 64 F -0.08 -0.08 13 13 
G7 POAG 64 F 0.1 0 14 14 
G8 POAG 62 M -0.02 -0.08 16 16 
G9 POAG 80 M 0.16 0.24 9 10 
G10 NTG 72 M 0 -0.1 10 10 
G11 NTG 67 M 0 0 12 12.5 
G12 POAG 77 M 0.1 0.26 13 16 
G13 POAG 76 F -0.08 0 8 10 
G14 POAG 63 M 0.14 -0.06 16 18 
G15 NTG 75 F 0 0 9 8 
G16 POAG 69 M -0.1 0 --- --- 
G17 POAG 71 M 0.02 0.14 --- --- 
G18 POAG 70 M 0.14 0.02 14 14 
G19 PXG 79 M 0.14 0.42 --- --- 
G20 PDG 59 M -0.1 0.34 18 12 
G21 POAG 80 M 0 0 --- --- 
G22 POAG 72 F 0.04 0.06 --- --- 
MEAN --- 70.32 --- 0.02 0.04 13.18 12.91 
SD --- 6.08 --- 0.10 0.15 2.92 2.75 
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TABLE 2. 
Demographic Information of Controls 
 
 
 
 
 
 
 
 
 
 
 
 
Controls did not have their IOP measured, but none of them had been diagnosed with 
ocular hypertension by their ophthalmologist and were expected to have IOP within 
the normal range. 
 
 
 
 
 
 
 
 Visual Acuity (logMAR) 
ID Diagnosis Age (years) Gender OD OS 
C1 Normal 45 F -0.1 -0.1 
C2 Normal 46 M -0.1 -0.1 
C3 Normal 72 M -0.08 -0.08 
C4 Normal 62 F -0.1 0 
C5 Normal 57 F -0.24 -0.1 
C6 Normal 58 M -0.28 0 
C7 Normal 58 M -0.04 -0.02 
C8 Normal 56 M -0.06 0.06 
C9 Normal 65 M -0.04 -0.10 
C10 Normal 50 M 0.00 -0.10 
C11 Normal 42 F -0.1 -0.1 
MEAN --- 
55.55 
--- 
-0.10 -0.06 
SD --- 
9.13 
--- 
0.08 0.06 
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TABLE 3. 
Demographic Information: Excluded Participants  
 
 
 
 
 
 
 
 
 
Only controls had to be excluded from the data analysis.  
CA, CG: they were suspected of having previously undetected glaucoma, based on the 
severity of their clinical tests (see Table 6). 
CB, CF:  they did not meet our inclusion criteria, as they had refraction outside of ±5 D. 
CC, CE: they had visual field data that was too severe for non-glaucomatous 
participants, as well as fleeting diplopia.  
CD: this participant felt panicked during the vection stimulus viewing, and we had to 
stop the experiment. CD may not have understood several of the other tasks as well. 
 
 
 
 
 
 Visual Acuity (logMAR) 
ID Diagnosis Age (years) Gender OD OS 
CA Suspect 72 F 0.24 0.14 
CB High Myope 55 F 0.02 -0.06 
CC Normal 52 F 0.12 0.16 
CD Normal 50 M 0.26 0.36 
CE Normal 76 M 0.3 0.22 
CF High Myope 48 F -0.1 -0.24 
CG Suspect 55 F 0 0 
MEAN --- 
58.29 
--- 
0.12 0.08 
SD --- 
11.09 
--- 
0.15 0.20 
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Clinical Information 
TABLE 4. 
Clinical Information: Patients with Glaucoma 
 
 
 
 
 MD (db) RNFL C/D Ratio CSFI 
 
ID OD OS OD OS OD OS OD OS 
G1 -0.43 -2.25 93 85 0.66 0.65 -2.02 16.05 
G2 -0.65 -3.34 78 67 0.73 0.77 17.59 36.82 
G3 -1.88 -1.17 92 90 0.64 0.59 10.02 4.47 
G4 --- -1.67 115 107 --- 0.4 --- -4.34 
G5 -2.11 -1.17 82 77 0.73 0.72 20.13 21.55 
G6 -3 -1.75 64 60 0.62 0.72 30.76 36.41 
G7 0.98 0.27 83 82 0.68 0.65 2.28 7.73 
G8 -0.63 -0.61 94 84 0.7 0.65 5.22 14.71 
G9 1.09 --- 90 94 0.66 0.66 -2.63 --- 
G10 -0.27 --- 74 80 0.76 0.69 24.88 --- 
G11 -0.08 --- 80 70 0.76 0.82 15.50 --- 
G12 -0.49 -3.5 102 94 0.7 0.66 -6.11 19.12 
G13 -1.61 -2.46 91 93 0.59 0.62 9.35 12.00 
G14 -1.2 -4.07 96 88 0.68 0.73 2.22 24.64 
G15 -1.68 -0.16 89 90 0.64 0.7 10.68 3.38 
G16 0.91 -1.66 76 65 0.52 0.45 6.63 25.20 
G17 -4.77 0.09 50 69 0.76 0.67 48.34 17.72 
G18 0.29 -0.57 76 77 0.69 0.66 13.22 15.25 
G19 -4.03 -1.34 79 101 0.71 0.59 30.96 15.67 
G20 --- --- 61 53 0.76 0.77 --- --- 
G21 -2.46 0.61 60 81 0.78 0.65 36.17 4.52 
G22 --- --- --- --- --- --- --- --- 
MEAN -1.16 -1.46 82.14 81.29 0.69 0.66 14.38 15.94 
SD 1.63 1.35 15.30 13.73 0.07 0.10 14.53 11.12 
 
MD: values were excluded if the amount of fixation losses or false positives surpassed 
our cut-off. 
RNFL and C/D Ratio: Inaccurate scans were discarded (eg. unable to identify the 
border of the optic disc, biologically impossible values). 
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CSFI: If at least one of MD, C/D Ratio, or RNFL could not be used, the CSFI could not be 
calculated. 
 
TABLE 5. 
 Clinical Information: Controls 
 
 
 MD (db) RNFL C/D Ratio CSFI 
 
ID OD OS OD OS OD OS OD OS 
C1 0.57 1.79 97 93 0.65 0.67 -2.93 -4.04 
C2 0.01 0.2 94 90 0.45 0.47 0.94 5.26 
C3 0.44 -0.83 80 73 0.55 0.56 7.32 18.22 
C4 -0.71 -0.38 81 83 0.52 0.42 10.65 8.69 
C5 1.58 0.51 84 77 0.46 0.55 -0.67 13.99 
C6 0.41 -3.26 82 91 0.6 0.32 4.79 12.49 
C7 2.61 3.05 106 97 0.46 0.47 -33.86 -23.83 
C8 -1.46 -0.88 106 104 0.63 0.6 0.59 -0.96 
C9 -0.98 -0.05 97 97 --- --- -4.77 -9.57 
C10 0.85 -0.19 91 86 0.69 0.66 -0.59 7.19 
C11 0.04 1.24 105 104 0.44 0.5 -7.40 -10.80 
MEAN 0.31 0.11 93.00 90.45 0.55 0.52 -2.36 1.51 
SD 1.15 1.63 10.17 10.10 0.09 0.11 11.68 12.68 
 
G9: the OCT scan did not accurately assess the borders of the optic disc, preventing the 
recording of a C/D ratio that was biologically possible. 
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TABLE 6. 
Clinical Information: Unused Data 
 
 MD (db) RNFL C/D Ratio CSFI 
 
ID OD OS OD OS OD OS OD OS 
CA -2.53 -0.85 72 71 0.70 0.71 31.72 27.10 
CB -0.93 -2.04 70 69 0.67 0.44 29.02 29.33 
CC -3.21 -3.63 106 101 0.57 0.61 8.76 14.94 
CD 0.38 -0.99 109 103 0.71 0.71 -11.84 -0.03 
CE -5.66 -3.02 84 87 0.65 0.68 33.75 15.92 
CF 0.55 0.65 73 74 0.46 0.33 21.21 14.27 
CG -1.49 -2.05 75 72 0.46 0.45 23.37 28.72 
MEAN -1.84 -1.70 84.14 82.43 0.60 0.56 19.43 18.61 
SD 2.18 1.44 16.59 14.60 0.11 0.15 16.12 10.62 
 
The reasons for excluding these participants are explained in Table 2. Note that the 
averages of the excluded controls appear closer to those of the patients.  
 
Apparatus 
 Vection Test 
Participants sat in front of a large, 130 x 130 degree projection screen at a 
viewing distance of 40cm. A rear projection system was utilized. The stimulus was a 
high contrast pattern of white dots (with a diameter of 2 deg) on a black 
background. The dots were in a random pattern with a density of 0.005 dots/deg2 
and they rotated at an angular speed of 45 deg/s. Stimulus rotation was in a 
clockwise motion, as if staring at a turning wheel from the side, in order to induce 
roll vection. The stimulus was created in VPixx (VPixx Technologies, Inc, Montreal, 
Quebec, Canada).  
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A button-response box was used to measure vection latency and duration. 
Vection-induced tilt was measured using a specially made tilt sensor attached to a 
headband. The amount of tilt is determined using one out of three total axes from an 
accelerometer (Freescale Semiconductors Inc, Austin, TX). The signal from the tilt 
sensor was sent to a laptop via a USB cable at a rate of 100 Hz. Subjective tilt ratings 
were obtained using a wooden joystick attached to a protractor that could be moved 
by the participant to indicate the amount they tilted during a trial. 
 
Procedure 
Participants were seated in a dark room in front of the projection screen. An 
eye patch was worn to cover one eye during each 2 minute trial. Participants were 
placed at a distance of 40 cm from the screen and instructed not to let their feet or 
knees touch either the screen or the ground. This was to avoid weakening the 
illusion of self-motion by making the participant feel anchored. 
Participants were told to look straight ahead with a relaxed gaze and not to 
follow any of the dots with their eyes. In the event that they felt vection, they were 
told to press and hold a response button for the entire duration of that sensation. If 
the feeling was intermittent, they could press and release the button several times 
in accordance with their personal experience. We used the button response box to 
report vection latency and total vection duration. 
A headband-mounted tilt sensor was also worn in order to measure upper 
body tilt as a more objective vection measure. Viewing the stimulus caused 
participants to instinctively tilt in the opposite direction, and participants were not 
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always aware of their own movement. One experimenter was always seated behind 
the participant to intervene in the event that the body tilt became so large that they 
were in danger of falling. The maximum tilt and mean tilt was measured for each 
trial. After each trial was over, participants reported their subjective tilt by moving a 
joystick on a protractor to estimate the angle of their maximum tilt.  
 
 Data analysis 
 
             A 2 x 2 [Group (glaucoma, control) x Eye (OD, OS)] mixed factorial ANOVA 
was run to determine if there was a significant difference in vection responses based 
on which eye was used. No significant main effect of eye was found (smallest p = 
.21), therefore all further analyses were independent t-tests or Pearson correlations 
looking at both eyes averaged together. For cases where data from only one eye 
could be used, the value obtained for that eye was considered to be the average. 
Only those who experienced vection were included in the analysis, as the vection 
latency was indeterminate if they never pressed the button. All statistical tests use 
an α level of .05.  
 
Results 
Forty-one percent (n=9) of patients with glaucoma, but only 9% (n=1) of 
control participants did not experience vection in any of the conditions (i.e., both left 
eye viewing and right eye viewing). It is interesting that so many patients were 
completely unable to experience vection, which demonstrates one aspect of the 
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dysfunctional vection responses of people with glaucoma. All individuals who did 
not experience vection were excluded from further analysis. The remaining sample 
contained 13 patients with glaucoma and 10 controls.  
The two groups were not age-matched, as the control group was significantly 
younger than the patients with glaucoma (t(21) = 4.4, p < .001). Our patient 
population also had significantly worse average visual acuity, visual field tests, and 
cup-to-disc ratio. 
 
TABLE 7.  
Between Groups (Glaucoma and Control) t-tests 
 
Comparison df t p 
Visual Field MD 20 3.82 0.001* 
RNFL 21 1.96 0.064 
Cup-to-Disc Ratio 21 3.68 0.001* 
CSFI 20 2.89 0.009* 
Visual Acuity 21 2.27 0.034* 
Age 21 4.40 < 0.001* 
 
Our patients had early stage glaucoma, but it was not so mild that they did not 
have noticeable deficits compared to controls.  
 
Vection Latency 
 
Patients with glaucoma did not have a significantly different vection latency 
than controls (t(21) = 1.85, p = .08). However, the data were highly variable in 
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patients with glaucoma, as the standard deviation was greater than the mean (M = 
27.63 s, SD = 30) and there was a positive skew (skewness = 1.67).  
 
Figure 1. Box plot of the vection latency of patients with glaucoma and 
controls. Note the wider spread of the data for the glaucoma group and the two 
outliers (patients 3 and 8) 
 
In order to correct for the abnormal spread of our data, we used a log 
transformation of the vection latency values for both groups. Doing this removed all 
outliers and reduced the positive skew of the data. This method found that the log of 
vection latency was significantly longer in patients with glaucoma (t(21) = 2.39, p = 
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.03), assuming unequal variances. The mean vection latency for the patients with 
glaucoma (M = 27.63 s) is just under three times as large as the control group (M = 
9.58 s). 
 
 
Figure 2. Box plot showing the log of vection latency of patients with glaucoma and 
controls.  
 
Vection Duration 
There was no significant difference for vection duration between the two 
groups (t(21) = 0.68, p = .50).  
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Figure 3. Vection duration with standard error bars 
 
Tilt 
Objective tilt measures in the glaucoma group also showed no significant 
difference from controls, including mean body tilt (t(21) = 0.29, p = .78) and max 
body tilt (t(21) = 0.26, p = .80). However, subjective ratings of mean body tilt were 
significantly lower in patients with glaucoma (t(21) = 2.12, p = .046). 
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Figure 4. Different tilt responses of patients with glaucoma and controls.  
 
Clinical Explanation of Vection Responses 
 
The main purpose of this study was to find an explanation for weaker vection 
responses in patients with glaucoma. As such, the following clinical measures were 
related to all the vection and tilt measurements in patients with glaucoma: CSFI, 
RNFL, cup-to-disc ratio, visual acuity, and visual field MD. There was no significant 
relationship between CSFI and vection latency or vection duration. A significant 
correlation was found between CSFI and subjective tilt estimates (r(11) = 0.75, p = 
.004). These results are contrary to our predictions, as it shows that a higher CSFI 
(more RGC loss) leads to higher subjective tilt estimates (a stronger sensation of 
vection).  Visual field MD also had a significant, negative correlation with subjective 
tilt estimates (r(11) = -0.70, p = 0.01). This was also contrary to our hypothesis, as 
0 
5 
10 
15 
20 
25 
Mean Tilt Maximum Tilt Subjective Tilt 
A
n
g
le
 (
d
e
g
re
e
s)
 
Glaucoma 
Control 
   * 
 
 
42 
high visual field MD (better visual functioning) was related to lower subjective tilt 
estimates. 
 
 
Figure 5. CSFI and subjective tilt in patients with glaucoma 
 
Figure 6. MD and Subjective Tilt in Patients with Glaucoma 
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Experiment 2 
Because 40% of patients in Experiment 1 did not experience vection, we used 
the Oculus Rift – a virtual reality system that displays images on a headset – in order 
to create a stronger sensation of vection. This headset provides an immersive 
environment that blocks out external stimuli in a way that was not possible for the 
projection screen in Experiment 1. This experiment also seeks to relate CSFI to 
weaker vection responses in patients with glaucoma, but using a stimulus that 
would ideally be strong enough to induce vection responses in more patients with 
glaucoma. Vection latency and duration was measured with the same button 
response box. Body tilt was not measured in this experiment because the stimulus 
induced circular vection. Instead, participants were asked to rate their subjective 
vection response on a numerical scale.  
 
Participants 
 For the group with mild glaucoma, we tested a total of 24 patients. Some 
patients did not meet our inclusion criteria, so the data of 21 patients (mean age, 
71.1 [±5] years) were used (see Table 8 caption for exclusion details). For this 
group, 38% (8/21) were female. There were two people of Asian descent, and one of 
African descent, while the rest of the group was white.  
The control group had a total of 23 participants with normal vision. We had 
to exclude those who did not meet our inclusion criteria, leaving us with 17 controls 
(mean age, 61.5 [±10] years) for the analysis (see Table 8 caption for exclusion 
details). Our two groups were not age-matched, despite our initial intentions to do 
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so, as obtaining a large enough age-matched sample was difficult. A t-test showed 
that the control group was significantly younger than the glaucoma group (t(21) = 
4.4, p < .001). Fifty-five percent (10/18) of the controls were female. Our control 
group contained three people of Asian descent, and one of African descent, while the 
rest were white.  
 
Demographic Information 
TABLE 8. 
 Demographic Information of Patients with Glaucoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Visual Acuity (logMAR) IOP 
ID Diagnosis Age (years) Gender OD OS OU OD OS 
G1 POAG 74 M -0.1 -0.1 -0.1 10 10 
G2 POAG 65 F 0.1 -0.1 -0.08 14 12 
G3 POAG 64 M 0 0 0 18 16.5 
G4 POAG 69 M 0 -0.1 0 --- --- 
G5 NTG 61 F 0.1 0 0.04 16 12 
G6 NTG 77 F 0.1 0 0.1 17 14 
G7 POAG 73 F -0.1 0 0 14 13.5 
G8 NTG 72 M --- 0 --- 12 15 
G9 LTG 75 M 0.1 0.1 0.14 13 13 
G10 POAG 72 M 0 0.1 0 13 13.5 
G11 POAG 75 M 0 0 0.02 6 10 
G12 POAG 70 M -0.1 0 0 13 13 
G13 NTG 65 M 0.1 0.1 0.06 10 10 
G14 NTG 67 M -0.08 0.02 -0.06 7 10 
G15 POAG 75 F -0.1 0.44 -0.1 12 13 
G16 POAG 68 M 0.12 0.28 0.04 13 8 
G17 NTG 73 M 0 -0.1 -0.1 14 12 
G18 LTG 69 F -0.04 --- -0.06 14 14 
G19 POAG 74 F 0.14 0.3 0.04 3 10 
G20 POAG 80 M 0.14 0.2 0.1 10 14.5 
G21 LTG 76 F 0.1 0.1 0 10 10 
MEAN --- 71.14 --- 0.02 0.06 0.00 11.95 12.20 
SD --- 4.86 --- 0.09 0.15 0.07 3.66 2.18 
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TABLE 9. 
Demographic Information of Controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
G8, G18: only one eye was tested because the other eye did not meet our inclusion 
criteria (secondary glaucoma due to a sports injury, or unilateral glaucoma only).  
G4:  IOP values were not available in the patient’s chart. 
C2-C6: We made an amendment to the protocol part way through and therefore only 
collected binocular data after the amendment. 
 
 
 
 Visual Acuity (logMAR) 
ID Diagnosis Age (years) Gender OD OS OU 
C1 Normal 74 M -0.1 -0.1 -0.08 
C2 Normal 62 F -0.1 0 --- 
C3 Normal 56 M -0.1 -0.1 --- 
C4 Normal 49 M 0.2 0.2 --- 
C5 Normal 54 M -0.1 -0.1 --- 
C6 Normal 52 F -0.1 -0.1 --- 
C7 Normal 54 F -0.1 -0.1 -0.02 
C8 Normal 47 M -0.3 -0.3 -0.1 
C9 Normal 68 F 0.1 0.1 0.06 
C10 Normal 70 F 0 -0.1 -0.1 
C11 Normal 65 F 0 -0.1 -0.06 
C12 Normal 62 M -0.1 -0.1 -0.1 
C13 Normal 49 F 0 0 0.04 
C14 Normal 75 F -0.1 0.1 0.1 
C15 Normal 59 F -0.1 -0.1 -0.1 
C16 Normal 71 F 0.4 0 0.02 
C17 Normal 79 M 0.2 0.04 0.04 
MEAN --- 61.53 --- -0.02 -0.04 -0.03 
SD --- 10.08 --- 0.16 0.11 0.07 
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TABLE 10.  
Demographic Information: Excluded Participants 
 
 
 
 
 
 
 
 
 
 
 
 
GA, GC: they did not understand many of the tasks. GC also had very poor clinical tests, 
indicating glaucoma that was closer to the moderate stage. 
GB: their visual fields were outside our inclusion criteria. 
CA: amblyopia was present in this participant. 
CB: visual acuity was outside out inclusion criteria. 
CC, CD: they displayed poor comprehension of all tasks, and fell asleep during testing. 
CE, CF: they were suspected of having early, undiagnosed glaucoma. 
 
 
 
 Visual Acuity (logMAR) IOP 
ID Diagnosis Age (years) Gender OD OS OU OD OS 
GA POAG 54 F 0 0.04 0.06 13 15 
GB POAG 73 M -0.1 -0.1 -0.1 12 11.5 
GC POAG 58 F -0.08 0.02 0 12 15 
MEAN --- 61.67 --- -0.06 -0.01 -0.01 12.33 13.83 
SD --- 10.02 --- 0.05 0.08 0.08 0.58 2.02 
CA Amblyopia 61 F -0.04 0.46 --- --- --- 
CB Normal 61 F 0.51 0.4 --- --- --- 
CC Normal 66 F 0 -0.06 0 --- --- 
CD Normal 50 F -0.1 0 0 --- --- 
CE Suspect 60 F 0.14 0.14 0.04 --- --- 
CF Suspect 74 F 0.1 0.04 0 --- --- 
MEAN --- 62 --- 0 0 0 --- --- 
SD --- 7.87 --- 0.22 0.22 0.02 --- --- 
 
 
47 
Clinical Information 
TABLE 11.  
Clinical Information of Patients with Glaucoma 
 
 MD (db) RNFL C/D Ratio CSFI 
 
ID OD OS OD OS OD OS OD OS 
G1 -0.93 -0.2 70 81 0.77 0.7 30.48 14.65 
G2 2.46 1.83 85 80 0.70 0.66 -7.02 3.90 
G3 1.01 0.2 95 86 0.70 0.64 -3.79 8.93 
G4 2.83 1.22 76 76 0.71 0.69 14.34 13.96 
G5 1.55 0.59 69 59 0.52 0.68 33.96 19.68 
G6 -2.5 -0.81 78 93 0.74 0.65 23.60 -2.77 
G7 --- -4 88 72 0.78 0.76 --- 35.60 
G8 --- -1.58 --- 93 --- 0.52 --- -0.54 
G9 -2.7 -0.75 76 73 0.85 0.77 13.30 18.77 
G10 -0.49 -1.52 72 71 0.7 0.67 21.37 25.18 
G11 0.12 1.57 70 84 0.8 0.71 24.60 4.56 
G12 --- --- --- --- --- --- --- --- 
G13 -1.53 -1.67 63 63 0.67 0.5 34.08 30.24 
G14 0.58 0.18 80 85 0.67 0.64 10.99 6.14 
G15 1.61 1.34 93 90 0.48 0.44 -19.85 -13.51 
G16 0.13 -4.58 70 61 0.72 0.78 22.19 43.99 
G17 --- --- 72 --- 0.67 --- --- --- 
G18 1.23 --- 75 --- 0.52 --- 14.24 --- 
G19 -1.1 -0.33 78 90 0.69 0.68 17.03 5.37 
G20 0.33 -2.82 76 85 0.6 0.59 6.44 12.26 
G21 2.52 1.84 99 87 0.68 0.74 -23.91 1.67 
MEAN 0.30 -0.53 78.16 79.39 0.68 0.66 12.47 12.67 
SD 1.68 1.91 9.71 10.80 0.10 0.09 17.28 14.42 
 
MD: values were excluded if the amount of fixation losses or false positives surpassed 
our cut-off. 
RNFL and C/D Ratio: Inaccurate scans were discarded (eg. unable to identify the 
border of the optic disc, biologically impossible values). 
CSFI: If at least one of MD, C/D Ratio, or RNFL could not be used, the CSFI could not be 
calculated. 
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TABLE 12. 
Clinical Information of Controls 
 
 
See Table 11 caption for explanation for missing data. 
 
 
 
 
 
 
 
 
 MD (db) RNFL C/D Ratio CSFI 
 
ID OD OS OD OS OD OS OD OS 
C1 -0.5 -1.36 78 71 0.57 0.54 11.89 18.94 
C2 -0.25 0.07 80 84 0.54 0.45 10.98 6.94 
C3 0.96 1.83 86 79 0.66 0.68 7.51 14.95 
C4 -0.02 -0.32 91 92 0.61 0.68 6.63 10.84 
C5 0.68 1.23 97 99 0.64 0.68 -3.05 -1.88 
C6 -2.15 -1 101 101 0.43 0.45 6.13 -0.65 
C7 -0.99 0.36 103 98 0.56 0.61 -1.41 -4.66 
C8 -0.66 -0.73 99 103 0.55 0.53 -1.02 -5.47 
C9 0.64 -0.34 70 66 0.58 0.56 17.25 23.06 
C10 0.22 -0.49 82 86 0.28 0.09 2.55 -1.47 
C11 -1.35 -4.34 104 111 0.66 0.64 -0.08 9.86 
C12 0.02 -0.75 85 85 0.49 0.33 4.97 6.47 
C13 -0.63 -1.3 96 93 --- --- --- --- 
C14 --- -0.26 83 86 0.7 0.57 --- 3.28 
C15 0.9 1.23 85 79 0.47 0.54 -0.24 8.99 
C16 --- -1.75 --- 93 --- 0.6 --- 5.22 
C17 3.15 1.65 101 98 0.54 0.55 -23.50 -12.83 
MEAN 0.00 -0.37 90.06 89.65 0.55 0.53 2.76 5.10 
SD 1.23 1.48 10.32 11.81 0.11 0.15 9.55 9.46 
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TABLE 13.  
Clinical Information of Participants Who Were Excluded 
 
Refer to Table 10 caption for reasons for exclusion. 
 
Apparatus 
Oculus Rift  
 The Oculus Rift (Oculus Rift DK2, Oculus VR, Irvine, CA) is a virtual 
reality system that displays a stimulus on a headset. The Oculus Rift can create an 
immersive environment that blocks out most external stimuli in ways a regular 
monitor cannot. This device allows for lighting and viewing distance to be held at a 
precisely constant level each time a participant is tested, and has a good test-retest 
reliability (Foerster et al., 2016). The Oculus Rift has a field of view of 100 degrees 
diagonally. This system has previously been used to examine vection responses in 
patients with glaucoma, although this was in the context of balance and fall 
 MD (db) RNFL C/D Ratio CSFI 
 
ID OD OS OD OS OD OS OD OS 
GA 0.02 -0.86 69 70 0.64 0.6 25.99 28.85 
GB -8.97 -7.07 68 67 0.58 0.64 48.11 46.31 
GC --- --- --- --- --- --- --- --- 
MEAN -4.48 -3.97 68.50 68.50 0.61 0.62 37.05 37.58 
SD 6.36 4.39 0.71 2.12 0.04 0.03 15.65 12.35 
CA -0.78 -6.98 98 97 0.53 0.59 -0.28 39.42 
CB -0.13 -0.42 69 86 0.49 0.37 23.22 6.92 
CC -4.50 -6.01 85 72 0.53 0.61 27.34 42.77 
CD -1.00 -0.83 101 106 0.6 0.59 -1.71 -6.07 
CE -3.65 -2.4 98 98 0.67 0.66 20.17 12.02 
CF -3.77 -2.4 79 74 0.7 0.72 31.39 28.92 
MEAN -2.31 -3.17 88.33 88.83 0.59 0.59 16.69 20.66 
SD 1.87 2.71 12.80 13.83 0.08 0.12 14.22 19.43 
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prevention (Diniz-Filho et al., 2015). Research has also shown the usefulness of the 
Oculus Rift for inducing vection in controls (Riecke & Jordan, 2015; Kim et al., 2015).  
 
 
Procedure 
 
For the vection test, participants wore the Oculus Rift headset with an eye 
patch covering one eye. The stimulus was a high contrast random-dot pattern. The 
dots were white on a black background, had a diameter of 1.5 deg, and the pattern 
had a density of 0.5 dots/deg2. The dot pattern rotated from left to right, as if 
displayed on the interior walls of a vertical cylinder. A fast (40deg/s) and slow 
(20deg/s) version of the stimulus was viewed monocularly (OD and OS) for a total 
of 4 conditions. Each condition lasted for 2 minutes.  
During the viewing period, participants used a response button to report 
vection latency and duration, by pressing and holding the button when they felt that 
they were moving. After each condition was over, participants reported their 
subjective vection strength using a 1-10 scale. A rating of 1 corresponded to the 
participant feeling as if the dots were moving and they were still (no vection), while 
a rating 10 corresponded to the participant feeling as if they were moving and the 
dots were still (full vection). 
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Data analysis 
 
  The results of 2 x 2 x 2 ANOVAs  (Group x Speed x Eye) on vection responses 
revealed that there was no main effect of the viewing eye (smallest p = .49). Since 
there was no significant different between values obtained with either eye, this 
allowed all values obtained binocularly to be averaged together. This allowed data 
analysis to be simplified to 2 x 2 mixed factorial ANOVAs. 
 The CSFI was related to vection responses using Pearson correlations. The 
two groups were compared on clinical measurements using independent-samples t-
tests. All tests used an alpha level of .05. 
 
Results 
 Twenty-four percent (N=5) of patients with glaucoma and 11% (N=2) of 
control participants did not experience vection at all. They were excluded from the 
following analyses, leaving a total of 15 controls and 16 patients with glaucoma. 
 Our patients were significantly worse than controls in several clinical 
measures, such as RNFL, cup-to-disc ratio, and CSFI. Patients were also significantly 
older than the control group, despite best attempts to age match the two groups. 
There were no significant differences between the two groups on all the functional 
clinical measures tested (visual field MD and visual acuity). 
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TABLE 14.  
Independent t-tests between patients and controls 
 
Comparison df t p 
Visual Field MD 28 0.01 0.993 
RNFL 28 2.91 0.007* 
Cup-to-Disc Ratio 27 3.39 0.002* 
CSFI 27 2.47 0.020* 
Visual Acuity 29 0.87 0.392 
Age 29 3.14 0.004* 
 
Table 14. Patients with glaucoma have functional vision measurements that are not 
significantly different from controls. It is only when we look at structural 
measurements that we see indications of glaucomatous damage. 
 
Vection Latency 
A 2 x 2 mixed factorial ANOVA of Group x Speed was run on vection latency, 
showing main effects of group, as well as speed on vection latency. Patients with 
glaucoma had significantly longer vection latencies than controls (F(1,26) = 5.77, p = 
.02). In addition, the fast condition produced shorter latencies (F(1,26) = 7.80, p = 
.01). The interaction between latency and velocity was not statistically significant. 
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Figure 7. Vection latency in the slow and fast condition 
In order to compare the statistical analyses of Experiments 1 and 2, a log 
transformation of the vection latency values was used in a 2 x 2 factorial ANOVA. 
The results still show a significant main effect of group (F(1,26) = 13.72, p = .001) 
and speed (F(1,26) = 5.96, p = .02) without a statistically significant interaction 
between these factors.  
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Vection duration 
There was no main effect of group (F(1,26) = 2.74, p = .10) or speed (F(1,26) = 1.94, 
p = .18) on vection duration. There was no interaction. 
 
 
Figure 8. Vection duration in the slow and fast condition. 
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Vection Strength 
 
 A main effect was seen for velocity on vection strength ratings, with the 
faster velocity resulting in higher ratings (F(1,26) = 22.41, p = .005). There was no 
interaction. 
 
 
Figure 9. Subjective vection strength rating in the slow and fast condition. 
 
Clinical Explanation of Vection Responses 
 
In order to explain these differences in vection responses, we related our 
vection measurements to all of our clinical tests (particularly, the CSFI) as well as 
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any vection measurements. This was seen for both speeds. Correlations were done 
separately for the slow and fast condition because some participants may have 
experienced vection with only one eye in the slow condition and only the other eye 
in the fast condition. For these cases, we only looked at vection results and clinical 
data from the eye that experienced vection.  
 
 
TABLE 15.  
Slow condition correlation values in patients 
 
 
Correlation df r p 
MD:Latency 12 -0.130 0.658 
MD:Duration 12 -0.151 0.606 
MD:Subjective Rating 12 -0.195 0.504 
RNFL:Latency 12 -0.256 0.377 
RNFL:Duration 12 0.079 0.788 
RNFL:Subjective Rating 12 -0.223 0.443 
C/D Ratio:Latency 12 -0.260 0.369 
C/D Ratio:Duration 12 0.281 0.330 
C/D Ratio:Subjective Rating 12 -0.174 0.552 
CSFI:Latency 12 0.212 0.467 
CSFI:Duration 12 0.012 0.967 
CSFI:Subjective Rating 12 0.100 0.734 
Acuity:Latency 12 -0.155 0.597 
Acuity:Duration 12 0.302 0.294 
Acuity:Subjective Rating 12 0.251 0.387 
Age:Latency 12 -0.108 0.713 
Age:Duration 12 0.443 0.113 
Age:Subjective Rating 12 0.241 0.407 
 
None of the correlations reached statistical significance. 
 
 
 
 
57 
 
 
TABLE 16.  
Fast condition correlation values in patients 
 
 
Correlation df r p 
MD:Latency 13 -0.367 0.178 
MD:Duration 13 0.312 0.258 
MD:Subjective Rating 13 -0.010 0.972 
RNFL:Latency 12 -0.257 0.375 
RNFL:Duration 12 0.348 0.204 
RNFL:Subjective Rating 12 -0.194 0.506 
C/D Ratio:Latency 13 -0.136 0.629 
C/D Ratio:Duration 13 0.143 0.611 
C/D Ratio:Subjective Rating 13 -0.304 0.271 
CSFI:Latency 12 0.301 0.276 
CSFI:Duration 12 -0.283 0.327 
CSFI:Subjective Rating 12 0.137 0.640 
Acuity:Latency 13 0.254 0.361 
Acuity:Duration 13 -0.311 0.259 
Acuity:Subjective Rating 13 -0.196 0.484 
Age:Latency 13 0.043 0.879 
Age:Duration 13 -0.170 0.545 
Age:Subjective Rating 13 0.195 0.486 
 
None of the correlations in the fast condition reached significance. The degrees of 
freedom is only 12 for visual field and CSFI comparisons. This is because in the fast 
condition only, a patient experienced vection in the same eye that had an invalid visual 
field test (due to high fixation losses). In this case, the “average” for both eyes would 
only use clinical data of this eye so the other visual field could not be used as a 
replacement. As such, without that visual field value, CSFI could not be calculated for 
that patient. 
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Summary and Concluding Discussion 
 
 The results of these two experiments support the original findings by Tarita-
Nistor et al. (2014) that vection latency is significantly longer in patients with early 
stage glaucoma. The fact that we were able to replicate these results twice is 
compelling evidence for the robustness of this effect. Unfortunately, each study 
utilized a slightly different stimulus and apparatus, making direct comparisons in 
vection strength between the three studies impossible.   
Experiment 1 and Experiment 2 sought to replicate the difference in vection 
responses seen by Tarita-Nistor et al. (2014), but the more important aspect was to 
try to explain why they occur. Patients were measured in a number of clinical 
measures to attempt to explain these findings.  
In Experiment 1, the patients had significant deficits in all clinical 
measurements except for RNFL thickness. It is understandable that a group with 
worse vision may not respond well to vection, particularly if they cannot see the 
stimulus well. However, in Experiment 2, the patients were not significantly 
different from controls in terms of functional measures of vision (both visual acuity 
and visual field MD). These patients had no visual deficits, yet they still experienced 
a notably weaker sensation of vection compared to controls. This suggests that the 
vection response is potentially affected before it is detectable by function-based 
clinical tests. It is interesting that patients with such early stage glaucoma have such 
weakened vection responses, to the point where many do not experience vection at 
all. 
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Understanding how these clinical measures affect vection responses is 
important for elucidating the effects of glaucoma on the visual-vestibular 
connection. Patients with glaucoma have worse postural stability than controls, as 
well as a greater likelihood of having fallen in the previous year (Diniz-Filho et al., 
2015). The capabilities of the vestibular system appears to be affected by both 
glaucoma as well as the natural aging process, as individuals rely more on vision for 
balance as their vestibular system weakens over time (Manchester et al., 1989). 
Furthering knowledge in this area may help prevent falls in this population. As such, 
we compared functional and structural clinical measures to vection responses. 
Experiment 1 showed that both visual field MD and CSFI were related to subjective 
tilt estimates. However, these correlations were in the opposite direction as 
expected, suggesting that more glaucomatous damage (detected using both 
structural and functional tests) lead to stronger vection ratings. Since visual field 
MD and CSFI did not correlate with actual body tilt, this suggests that participants 
are highly inaccurate at judging the movement of their own body. For example, 
compared to their mean tilt (M = 5.82 degrees, SD = 4.28 degrees), patients with 
glaucoma overestimated the amount they tilted by almost double (M = 10.35 
degrees, SD = 7.34 degrees). Participants had to physically move a joystick on a 
protractor to estimate their tilt, and some participants may not have a good grasp on 
how the angle on a small protractor corresponds to the angle of their entire upper 
body. The reason estimates are larger instead of smaller may be because patients 
with glaucoma have a weaker sense of balance. Patients with glaucoma are three 
times more likely to have fallen in a given year, compared to age-matched controls 
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(Kotecha et al., 2012; Haymes et al., 2007). This fear of falling may make these 
patients more anxious about precarious body positions, leading to overestimations 
in body tilt. This high level of inaccuracy may reduce the validity of this measure and 
any correlation that was found with it.  
It is important to note that we can already differentiate very mild glaucoma 
from controls in terms of their vection responses. It appears that vection is either 
impaired or entirely absent in these patients. However, it is still unclear what 
precisely causes these weaker responses, as none of our clinical measures were 
related to them in Experiment 2. It is a puzzling matter.  
Perhaps the lack of significant correlations is due to the narrow range of data 
values. We are only looking at early stage glaucoma, meaning that we were only 
comparing vection responses to clinical values on the low end of the scale. However, 
since such a large proportion of patients with even mild glaucoma did not 
experience vection at all, we avoided more severe cases.  
The lack of a correlation between the CSFI and vection responses may also be 
due to the nature of the CSFI itself. The CSFI groups all RGCs together to calculate 
gross loss, without separating the cells into their specific subtypes. The CSFI also 
does not take the accessory optic system into account. This is partocularly 
important for these experiments, as one of the functions of the accessory optic 
system is to relay visual-vestibular interactions to the brainstem (Giolii, Blanks, & 
Lui, 2006). One would expect that a loss of these neurons in particular would lead to 
weaker vection responses. However, this was not measured by the CSFI, and further 
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demonstrates the need for an fMRI study to better understand the pathways 
affected by glaucoma.  
It may be that the clinical tests we chose did not capture the reasons for 
weaker vection responses, and that there must be another clinical measurement 
that provides an explanation.  For example, the cause of these weaker vection 
responses may be due to glaucoma having an effect on cortical structures. This sort 
of loss is not readily captured by standard clinical tests for glaucoma such as the 
visual field test and OCT. Vection is a very complex response that results from 
conflict between the visual and vestibular system. An area of the visual cortex called 
V6 has been shown to be preferentially activated during the sensation of vection 
(Wada, Sakano, & Ando, 2016). However, glaucoma has been shown to damage the 
visual cortex, which may make it more difficult for the visual system to override the 
vestibular system to cause the illusion of self-motion (Gupta et al., 2006). Future 
studies should  look into correlating fMRI responses during vection in patients with 
glaucoma as well as controls with healthy vision. It would then be expected that 
patients with glaucoma experience less visual cortex activation during vection, 
which is why their vection response is dampened.  
Another possibility is that vection responses were weakened due to reduced 
contrast sensitivity, which is very common in patients with glaucoma (McKendrick 
et al., 2007). Contrast sensitivity has been shown to decline in patients with 
glaucoma even before changes in visual acuity and visual field tests (Ross, Bron, & 
Clark, 1984; Wilensky & Hawkins, 1989; Regan & Neima, 1984). Therefore, it is 
possible our patient sample had reduced contrast sensitivity despite having very 
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early stage glaucoma. Furthermore, contrast sensitivity has been shown to affect 
vection responses, with lower contrast stimuli producing weaker vection responses 
in controls at either low or high (but not intermediate) speeds (Holten et al., 2016). 
A contrast sensitivity test may explain why vection responses were weaker in these 
patients. 
The vestibular system naturally decays with age (Agarwal et al., 2009). This 
can result in a higher rate of falls as well as a stronger sensation of vection in the 
elderly (Sattin et al., 1990; Paige, 1994). Both the vestibular and visual system 
deteriorate with age, however, there is more reliance on the visual system in the 
elderly (Haibach, Slobounov & Newell, 2008); therefore, vection responses may be 
stronger in the elderly because visual stimuli can more easily override the 
vestibular system as the dominant input. However, elderly patients with glaucoma 
tend to have a loss of peripheral vision. This may explain why vection responses are 
paradoxically weaker in this older population, as they are relying on vision despite 
the fact that their peripheral vision is compromised. For example, patients with 
glaucoma are three times more likely to fall or have issues with locomotion than 
age-matched controls (Haymes et al., 2007). Tasks reliant on peripheral vision such 
as these are more negatively affected in patients with glaucoma due to this pattern 
of vision loss. 
 
Experiment 2 showed a significant main effect for speed on vection latency 
and subjective vection rating. That is, for the faster speed, vection latency was 
shorter and the subjective vection rating was higher. This is consistent with the 
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literature showing that vection strength increases with the speed of the stimulus, up 
to a certain threshold (Brandt et al., 1973). 
Detecting glaucoma at an earlier stage is particularly important for patient 
prognosis. Glaucoma has been coined “the silent thief of sight”, as it often robs the 
patient of vision without them being aware of it until it reaches the intermediate to 
later stages. Once the damage is done, it is irreversible. This is why it’s so important 
to begin monitoring for glaucoma as soon as possible to minimize the damage. 
Looking for potential early markers for glaucoma, such as reduced vection 
responses, could help in the search for developing more efficient screening tools for 
glaucoma. Even when patients are seen by an ophthalmologist, glaucoma can be 
undiagnosed in up to 50% of cases (Topouzis et al., 2007). Any addition to the 
battery of tests used to diagnose glaucoma may help lower this number. The Oculus 
Rift is very promising as a potential screening device, given its compact size, 
affordability, portability and ease of use. In this test, it is very clear if there is a 
sensation of self-motion or not, making it intuitive for both patients and clinicians. 
Work has yet to be done on whether these results are specific only to glaucoma, but 
the potential exists for this to be used as a screening device. If this test is successful, 
catching glaucoma at an earlier stage can lead to earlier treatment and better 
patient outcomes.  
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Limitations 
 
Several participants reported feeling “weird” or “floating” instead of typical 
descriptors of vection. It is difficult to know whether they experienced an entirely 
different sensation from vection or if they simply did not know how to describe it.  
There were a considerable number of patients with glaucoma who did not 
experience vection in Experiment 1. This may be because the room was visible in 
the periphery. This would make the stimulus appear in the foreground with the rest 
of the room in the background. However, stimuli seen as being in the foreground or 
closer to the viewer tend to reduce vection responses (Post et al., 1988; Howard & 
Heckmann, 1989). This may be why almost half of our patients with glaucoma were 
unable to experience vection, as their perception was weakened by the stimulus 
appearing in the foreground against a stationary background.  
The controls were significantly younger than the glaucoma group in both 
experiments. This may have posed a problem in terms of vection responses, as 
motion sensitivity tends to decrease with age (Falkenberg & Bex, 2007; Wills & 
Anderson, 2000). However, we believe this does not invalidate our results as other 
studies show that induced circular vection (Paige, 1994) and certain types of motion 
detection (Hutchinson, Ledgeway, Allen, 2014; Betts et al., 2005) actually may 
become stronger with age. Elderly individuals rely more on their visual system than 
their vestibular system (Haibach, Slobounov & Newell, 2008), which may cause 
them to get “tricked” more easily by a vection stimulus into thinking they are 
actually moving. Since our patients are older, we would then expect them to actually 
have a stronger sensation of vection, but we found the opposite. As such, we believe 
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this age difference does not invalidate our results. If anything, it shows just how 
robust the effect of glaucoma is on reducing vection responses. 
Finally, the sample size was rather small for each experiment. It would have 
been ideal to test the same participants on the projection screen and then the Oculus 
Rift to increase the number of participants and compare their responses across 
experiments. 
 
 
Conclusions 
Although our groups were not age-matched, it is still possible to come to the 
conclusion that patients with early stage glaucoma experience either a weakened 
sensation of vection, or no vection at all. Even when these patients do not 
significantly differ from controls in terms of visual field tests or visual acuity, we still 
see a stark contrast in how vection is experienced. We could not find a correlation 
between CSFI and vection responses, suggesting that another component of 
glaucoma is responsible for these weakened vection responses. Future studies can 
broaden the scope of clinical tests (such as including fMRI or contrast sensitivity 
tests) to find an explanation for the difference in how these patients experience 
vection. Furthermore, the vection test on the Oculus Rift may be able to help screen 
for glaucoma at an early stage, which would improve patient outcomes. 
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Appendix A: Visual Fields and OCT 
The visual field test is a gold standard clinical test used to assess and track 
the progression of glaucoma. The patient sits down and places their head on a 
chinrest; positioned so that one eye is centered with a fixation light. The other eye is 
covered with a black eye patch. Every time the patient sees a small, flashing light, 
they press a button. The light will appear in a random location each time. Gradually, 
the brightness of the lights will decrease until a threshold is reached where they can 
no longer perceive the light. During the entire testing period, the patient must keep 
their eyes focused on the fixation light. Along with verbal reminders to maintain 
fixation, video monitoring of the eye and manual repositioning of the chinrest 
ensured minimal fixation loss. 
The 24-2 SITA-standard test assesses vision on a 54-point grid. As such, it is 
able to assess both central and non-extreme peripheral vision deficits. SITA-
standard is the name of the algorithm, which determines the threshold based on a 
staircase method. This method is more reliable than the SITA-fast, as it has smaller 
jumps down in brightness in response to correct answers, although it also takes 
longer to run. Each eye takes approximately 5 minutes to test. 
There is a value at each eccentricity (distance from the centre) assigned in 
decibels for the dimmest light that person could see. For clinical use, these values 
are conveniently averaged into the MD (also measured in decibels), which is scaled 
to the patient’s age. A positive value indicates that the patient is performing better 
than an age-matched, normal population, whereas a negative value indicates the 
opposite. For example, a score of -3dB means that the patient scored 0.3 log units 
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less than an age-matched control. The lowest possible value is -30dB. According to 
the Hodapp-Parish-Anderson (HPA) staging system, mild stage glaucoma is 
classified as have an MD somewhere around -6 dB, although normal eyes generally 
score higher than -2 dB (Hodapp et al., 1993; Smith et al., 2014). The severity of 
glaucoma can also be determined based on clusters of adjacent points that have 
abnormally low dB values, but this was not used for our method for finding patients 
with only mild visual field defects (Smith et al., 2014).  
 
 
Figure 10. Visual field test example print-out 
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All the visual field information that is used to calculate the CSFI is marked by 
blue numbers in Figure 10. The grid seen in (1) is essentially a map of retinal 
sensitivity based on average values from an age-matched control. Values closest to 
the centre of the axis are representative of the macula and those farthest represent 
the periphery. High values indicate that the patient is performing well and can 
perceive very dim lights. The value of <0 is the natural blind spot where the optic 
nerve exits the eye. The values in the grid are summarized in (2) as the MD, which 
represents the difference in mean visual sensitivity from the average result of an 
age-matched population.  
OCT is another clinical test commonly used in the screening and monitoring 
of glaucoma. We used spectral-domain Cirrus HD-OCT, which was currently being 
used by our patients’ clinician to monitor their progress. Spectral domain OCT has 
been shown to have a better axial resolution, test-retest variability, and sensitivity 
for the detection of glaucoma than time domain OCT  (Drexler et al., 2001). Spectral 
domain OCT uses light to obtain a cross-sectional image of the retina. There is a 
reference beam and a sample beam. The sample beam hits the patient’s retina and is 
reflected back in a way that interferes with the reference beam. This interference is 
then picked up by the OCT, allowing it to form measurements of depth (Drexler et 
al., 2001). The 200 x 200 Optic Disc Cube scan that we used in both experiments 
covers a 6mm square grid that is centered around the optic disc.  
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Figure 11. OCT Example Print-out. The values of an OCT scan are colour-coded based 
on the (age-matched) probability values of normal. For example, any value in green or 
white indicates a healthy value within a normal population (p > 0.95) and any value in 
red is far outside the normal range (p < 0.01). 
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The OCT values used to calculate the CSFI and for data analysis are marked 
by blue numbers in Figure 11. Glaucoma causes the death of RGCs at the RNFL, 
which thins the retina and can lead to dysfunctional vision. Damage is also often 
seen at the optic nerve head, which can change the optic disc area. The software of 
the OCT defines the edge of the disc as where Bruch’s membrane ends (Puliafito, 
2009). Both RNFL thickness (1) and optic disc area (2) are used to calculate the 
CSFI. Additionally, we look at the average cup-to-disc ratio (3), although this is not 
part of the CSFI calculation. The cup-to-disc ratio compares the diameter of the 
entire optic disc to the “cupping” area inside of it, where the retina forms a small pit 
for the axons to exit the eye. The cup does not contain nerve fibers. In some cases of 
glaucoma, the disease progression (usually high pressure) can lead to an increase in 
the cupping area. A larger cup-to-disc ratio usually implies that there has been 
glaucomatous damage, as the area of non-functional retina is increasing. However, 
every individual has their own baseline cup-to-disc ratio, so this average may vary 
between people. Therefore, a high cup-to-disc ratio may not necessarily be due to 
glaucoma. It’s when the cup-to-disc ratio starts to stray from this baseline level that 
it becomes a stronger indicator of the progression of glaucoma. 
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Figure 12. Close-up of the optic nerve measurement from an OCT print-out. This 
patient has a moderate level of pathological cupping, as the cup is almost as large as 
the disc. The inner cup is outlined by a red circle, while the outer border of the optic 
disc is outlined by a black circle. 
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Appendix B 
 
 
 
 
Figure 13. Experiment 1 stimulus. The random dot pattern rotated around a central 
point in order to induce roll vection 
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Figure 14. Experiment 2 stimulus. The random dot pattern was placed on the walls of 
a virtual cylinder, which rotated around the observer who appeared to be seated in the 
centre. This induced circular vection. 
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Appendix C: Informed Consent 
 
 
Vision Science Research Program 
 Toronto Western Hospital 
  
 
 
Consent Form to Participate in a Research 
Study 
 
TITLE: Self-Induced Motion in Patients with Glaucoma 
 
INVESTIGATORS:  Dr. Esther González  
 Dr. Luminita Tarita-Nistor  
 Dr. Martin Steinbach  
 Dr. Graham Trope  
 Taylor Brin  
   
   
Introduction   
You are being asked to take part in a research study. Please read this explanation 
about the study and its risks and benefits before you decide if you would like to take 
part. You should take as much time as you need to make your decision. You should 
ask the study doctor or study staff to explain anything that you do not understand 
and make sure that all of your questions have been answered before signing this 
consent form. Before you make your decision, feel free to talk about this study with 
anyone you wish. Participation in this study is voluntary. 
 
Background 
Glaucoma is the second leading cause of blindness worldwide affecting an estimated 
3% of the population over 40 years of age. The scenes that people with glaucoma 
can see become progressively smaller. We refer to this as a loss of the peripheral 
vision. Due to the nature of their loss, patients with glaucoma experience difficulties 
finding places when they walk, and are more likely to fall or to be involved in a car 
accident than people with normal vision of similar age. Large moving scenes can 
induce a sensation of self-motion in people with healthy vision. This self-induced 
motion is called vection and depends on the peripheral vision. The present study 
investigates whether patients with glaucoma experience vection differently.  
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Purpose 
We do not know whether self-induced motion (vection), which depends on peripheral 
vision, is affected in people with glaucoma. Therefore, the purpose of this research is to 
examine the function of peripheral vision by testing if people with glaucoma experience 
vection in the presence of large, moving scenes. This research will help us understand 
more about the problems of people with glaucoma.  
 
Procedures 
The study will take place at the Ocular Motor Laboratory, located at the Toronto Western 
Hospital, University Health Network. Testing will be done in one visit and it will last 
about 40 minutes.  
 
We will examine your sensitivity to experience vection using moving scenes that we will 
project on a large screen. You will be seated in front of the screen and asked to press a 
button when you have a sensation that you are moving. After this testing, you will be able 
to leave. 
 
Risks Related to Being in the Study 
There are no additional medical risks due to study procedures. You may 
experience a slight motion sickness; we will stop any time you feel you are not 
comfortable. 
 
Benefits to Being in the Study 
There are no direct benefits to you from participating in this study. You may benefit from 
participating in this study by learning how strongly you can experience self-motion. In 
the future, the information from this study will help people with your condition 
understand more about their deficits. 
 
Confidentiality  
If you agree to join this study, the study doctor and his/her study team will look at 
your personal health information and collect only the information they need for the 
study.  Personal health information is any information that could be used to identify 
you and includes your: 
 name,  
 address,  
 date of birth,  
 new or existing medical records, that includes types, dates and results of 
medical tests or procedures.   
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The information that is collected for the study will be kept in a locked cabinet in a 
restricted area by the study doctor for 7 years.  Only the study team or the people or 
groups listed at the beginning of this form will be allowed to look at your records.  
Your participation in this study may also be recorded in your medical record at this 
hospital.   
 
Representatives of the University Health Network Research Ethics Board may look 
at the study records and at your personal health information to check that the 
information collected for the study is correct and to make sure the study followed 
proper laws and guidelines. 
 
All information collected during this study, including your personal health 
information, will be kept confidential and will not be shared with anyone outside 
the study unless required by law.  You will not be named in any reports, 
publications, or presentations that may come from this study.   
 
If you decide to leave the study, the information about you that was collected before 
you left the study will still be used.  No new information will be collected without 
your permission.  
 
Voluntary Participation 
Your participation in this study is voluntary. You can choose not to participate or you 
may withdraw at any time without affecting your medical care.  
 
In Case You Are Harmed in the Study 
If you become ill, injured or harmed as a result of taking part in this study, you will receive 
care. The reasonable costs of such care will be covered for any injury, illness or harm that is 
directly a result of being in this study. In no way does signing this consent form waive your 
legal rights nor does it relieve the investigators, sponsors or involved institutions from their 
legal and professional responsibilities. You do not give up any of your legal rights by signing 
this consent form.  
Questions about the Study 
 
If you have any questions, concerns or would like to speak to the study team for any 
reason, please call Dr. Esther G. González or Dr. Luminita Tarita-Nistor or Ms. Taylor 
Brin. 
 
If you have any questions about your rights as a research participant or have concerns 
about this study, please call the Chair of the University Health Network Research Ethics 
Board (REB) or the Research Ethics office number.  The REB is a group of people who 
oversee the ethical conduct of research studies. These people are not part of the study 
team. Everything that you discuss will be kept confidential. 
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Consent  
This study has been explained to me and any questions I had have been answered. 
I know that I may leave the study at any time. I agree to take part in this study.  
 
         
  
Print Study Participant’s Name  Signature  Date  
 
(You will be given a signed copy of this consent form) 
 
 
My signature means that I have explained the study to the participant named above. 
I have answered all questions. 
 
         
  
Print Name of Person Obtaining Consent Signature  Date  
 
 
Was the participant assisted during the consent process?  YES  NO 
If YES, please check the relevant box and complete the signature space below: 
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 The person signing below acted as a translator for the participant during the consent 
process and attests that the study as set out in this form was accurately translated and has 
had any questions answered..  
 
        
Print Name of Translator  Signature   Date 
 
 
            
Relationship to Participant   Language 
 
 The consent form was read to the participant. The person signing below attests that 
the study as set out in this form was accurately explained to, and has had any 
questions answered. 
 
 
        
Print Name of Witness   Signature   Date 
 
 
      
Relationship to Participant  
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Appendix D: Glossary 
 
Amblyopia: A visual disorder where input from an otherwise physically healthy eye 
is suppressed at the level of the visual cortex. 
 
Apoptosis: Programmed cell suicide. 
 
Anterograde trans-synaptic degeneration: The death of neurons due to the 
disruption of signaling from adjacent neurons responsible for input. 
 
Aqueous fluid / intraocular fluid: The fluid located within the eye, which 
maintains a certain pressure to keep the structure of the eye in tact. 
 
Bruch’s membrane: One of the many layers of the retina, it allows for the transport 
of fluid and structurally supports the other layers. 
 
Calcarine sulcus: A neuroanatomical region that resembles a small fissure, and 
divides the visual cortex into two portions. 
 
Cerebrospinal fluid: A protective fluid found in the brain and spinal cord. 
 
Conjunctiva: A thin layer of protective mucous that covers the sclera and the inside 
of the eyelids. 
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Contrast sensitivity: The ability to distinguish between light and dark. 
 
Corpus callosum: A system of axons that connect the left and right hemisphere of 
the brain. 
 
Enucleation: The process of removing one or both eyes. This is usually done as a 
result of some sort of traumatic injury or disease. 
 
Fovea: The area of the retina that has the highest level of acuity. It is located in the 
centre of the macula, and is used during fixation. 
 
Iris: The coloured part of the eye which changes size in order to let more or less 
light into the pupil. 
 
Lamina cribrosa: A meshwork that allows optic nerve fibres to pass through and 
reach the sclera 
 
Lateral geniculate nucleus: This brain structure relays information from the visual 
pathway to the thalamus. 
 
Lens: The lens of the eye refracts light to allow the viewer to focus at a specific 
depth. The shape of the lens changes to ensure the object of focus is seen as clearly 
as possible.  
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logMAR: A log-based unit to describe visual acuity more precisely than the Snellen 
chart, although logMAR can also be converted into Snellen. 
 
Macula: An area of high visual acuity in the retina. This area includes the fovea and 
the surrounding retinal tissue. 
 
Magnocellular pathway: This visual pathway is specific for contrast, spatial 
orientation, and motion detection. 
 
Neuroretinal rim area: The border around the optic disc where neural tissue is 
found, just before the physiological cupping area begins. 
 
Ocular hypertension: A condition where pressure inside the eye is unusually high. 
This can lead to optic nerve damage and/or glaucoma. 
 
Optic nerve: A bundle of axons that carries visual information from the retina to the 
brain. The area that the optic nerve exits the eye creates a natural blind spot. 
 
Proprioceptive system: A sensory system that provides information about the 
position of the body in space. 
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Refractive error: The result of not being able to accurately focus at either near or 
far distances. Refractive error can be measured in order to obtain an appropriate 
glasses prescription. 
 
Retinal ganglion cells: This subtype of neurons can be found near the surface of 
the retina. It is part of a system of cells that transmits visual information from the 
retina to the brain. 
 
Saccade: A quick eye movement used to change the fixation target.  
 
Schlemm’s canal: A circular passage in the eye where aqueous humour flows in 
order to reach blood vessels on the sclera. 
 
Sclera: The opaque, white region of the eye. 
 
Scotoma: An isolated area where a portion of the visual field has been lost or 
diminished due to disease or injury.  
 
Somatosensory system: This system provides information about one’s immediate 
environment through touch, pain, temperature, and the movement of the body. 
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Spatial frequency: The measurement of detail in a stimulus. A stimulus with a high 
spatial frequency has sharp edges and very fine details, while a low spatial 
frequency stimulus appears blurry. 
 
Temporal cortex: Part of the cerebral cortex, this region of the brain is thought to 
be primarily responsible for visual memory, language, and emotion. 
 
Trabecular meshwork: This structure allows for aqueous humour to exit the 
anterior chamber through Schlemm’s canal. 
 
Vestibular system: This system controls balance using a variety of different input, 
including vision and the sensation of our position from inner ear organs. 
 
Visual cortex: An area of the brain responsible for processing visual information. 
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